Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01006252
Registration number
NCT01006252
Ethics application status
Date submitted
30/10/2009
Date registered
1/11/2009
Date last updated
17/07/2018
Titles & IDs
Public title
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
Query!
Scientific title
A Randomized Phase 3 Study of Tasisulam-sodium Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle Versus Paclitaxel as Second-line Treatment in Patients With Metastatic Melanoma
Query!
Secondary ID [1]
0
0
H8K-MC-JZAO
Query!
Secondary ID [2]
0
0
13101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SUMMIT-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tasisulam-sodium
Treatment: Drugs - Paclitaxel
Experimental: Tasisulam-sodium - Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
Active Comparator: Paclitaxel - Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
Treatment: Drugs: Tasisulam-sodium
Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
Treatment: Drugs: Paclitaxel
80 mg/m^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is duration from enrollment to death; OS censored for participants who were alive at last contact.
Query!
Timepoint [1]
0
0
Randomization to date of death from any cause (assessed at every cycle and every 60 days following treatment discontinuation) up to 14.32 months
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is time from date of first dose to first observation of disease progression (PD); PD=20% increase in sum of the longest diameter of target lesions, or death from any cause.
Query!
Timepoint [1]
0
0
Randomization to date of objectively determined PD, or death from any cause (assessed at every cycle and every 60 days following treatment discontinuation) up to 13.70 months
Query!
Secondary outcome [2]
0
0
Percentage of Randomized Participants Having a Confirmed Best Response of Partial Response (PR) or Complete Response (CR)
Query!
Assessment method [2]
0
0
Response Evaluation Criteria In Solid Tumors (RECIST) criteria: CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; Progressive disease (PD)=20% increase in sum of the longest diameter of target lesions.
Query!
Timepoint [2]
0
0
First date RECIST criteria met for CR or PR (whichever occurred first) until first date of documented PD, or death from any cause (assessed every other cycle) up to 13.70 months
Query!
Secondary outcome [3]
0
0
Duration of Response (DoR) for Participants Having an Objective Response of Partial Response (PR) or Complete Response (CR)
Query!
Assessment method [3]
0
0
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; Progressive disease (PD)=20% increase in sum of the longest diameter of target lesions. Analysis was adjusted for Baseline Lactate Dehydrogenase (LDH); Disease Stage; Sex; Previous Single Agent Immunotherapy Treatment; Age Group. Due to limited number of responses for either treatment arm, DoR analysis was not performed.
Query!
Timepoint [3]
0
0
First date RECIST criteria met for CR or PR (whichever occurred first) until first date of documented PD, or death from any cause (assessed every other cycle) up to 13.70 months
Query!
Secondary outcome [4]
0
0
Percentage of Randomized Participants Having a Confirmed Best Overall Response of Partial Response (PR) or Complete Response (CR) Plus Participants With an Overall Response of Stable Disease (SD)
Query!
Assessment method [4]
0
0
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; SD=small changes that do not meet above criteria; PD=20% increase in sum of the longest diameter of target lesions.
Query!
Timepoint [4]
0
0
First date RECIST criteria met for CR, PR, or SD until first date of documented progressive disease (PD), or death from any cause (assessed every other cycle) up to 13.70 months
Query!
Secondary outcome [5]
0
0
Time to Deterioration in the Functional Assessment of Cancer Therapy-Melanoma Trial Outcome Index (FACT-M TOI) Score
Query!
Assessment method [5]
0
0
FACT-M measures domains of health-related quality of life (HR-QoL): physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns of melanoma. FACT-M TOI is the sum of FACT-M physical well-being, functional well-being, and melanoma subscales. Scores range from 0 to 120; Higher scores=better quality of life (QoL). FACT-M TOI score deterioration was defined as time from randomization to a minimally important difference in TOI score or death.
Query!
Timepoint [5]
0
0
Randomization to first date of deterioration in FACT-M TOI, or death from any cause (assessed every cycle and up to 30 days following treatment discontinuation) up to 13.21 months
Query!
Secondary outcome [6]
0
0
Change From Baseline at Cycle 2 in Functional Assessment of Cancer Therapy-Melanoma (FACT-M) up to 30 Days Following Treatment Discontinuation
Query!
Assessment method [6]
0
0
FACT-M measures domains of health-related quality of life (HR-QoL): physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns of melanoma. Total scores range from 0 to 172; Higher scores=better HR-QoL. Least Squares (LS) Mean value was adjusted for treatment group, cycle, treatment-by-cycle interaction, age, Eastern Cooperative Oncology Group (ECOG) performance status, stage of disease at study entry, and best response to previous chemotherapy.
Query!
Timepoint [6]
0
0
Baseline at Cycle 2, up to 30 days following treatment discontinuation
Query!
Secondary outcome [7]
0
0
Change From Baseline at Cycle 3 in Functional Assessment of Cancer Therapy-Melanoma (FACT-M) up to 30 Days Following Treatment Discontinuation
Query!
Assessment method [7]
0
0
FACT-M measures domains of health-related quality of life (HR-QoL): physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns of melanoma. Total scores range from 0 to 172; Higher scores=better HR-QoL. Least Squares (LS) Mean value was adjusted for treatment group, cycle, treatment-by-cycle interaction, age, Eastern Cooperative Oncology Group (ECOG) performance status, stage of disease at study entry, and best response to previous chemotherapy.
Query!
Timepoint [7]
0
0
Baseline at Cycle 3, up to 30 days following treatment discontinuation
Query!
Secondary outcome [8]
0
0
Change From Baseline at Cycle 4 in Functional Assessment of Cancer Therapy-Melanoma (FACT-M) up to 30 Days Following Treatment Discontinuation
Query!
Assessment method [8]
0
0
FACT-M measures domains of health-related quality of life (HR-QoL): physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns of melanoma. Total scores range from 0 to 172; Higher scores=better HR-QoL. Least Squares (LS) Mean value was adjusted for treatment group, cycle, treatment-by-cycle interaction, age, Eastern Cooperative Oncology Group (ECOG) performance status, stage of disease at study entry, and best response to previous chemotherapy.
Query!
Timepoint [8]
0
0
Baseline at Cycle 4, up to 30 days following treatment discontinuation
Query!
Secondary outcome [9]
0
0
Change From Baseline at Cycle 2 in EuroQol-5 Dimensions (EQ-5D) up to 30 Days Following Treatment Discontinuation
Query!
Assessment method [9]
0
0
EQ-5D consists of 5 items that assess participant's overall health. Participants choose 1 of 3 options that best describe the status of each item. EQ-5D United Kingdom (UK)-based index scores range from -0.59 (worst health) to 1.0 (1.0=perfect health; Positive change from baseline=health improvement). Least Squares (LS) Mean value was adjusted for treatment group, cycle, treatment-by-cycle interaction, age, Eastern Cooperative Oncology Group (ECOG) performance status, stage of disease at study entry, and best response to previous chemotherapy.
Query!
Timepoint [9]
0
0
Baseline at Cycle 2, up to 30 days following treatment discontinuation
Query!
Secondary outcome [10]
0
0
Change From Baseline at Cycle 3 in EuroQol-5 Dimensions (EQ-5D) up to 30 Days Following Treatment Discontinuation
Query!
Assessment method [10]
0
0
EQ-5D consists of 5 items that assess participant's overall health. Participants choose 1 of 3 options that best describe status of each item. EQ-5D United Kingdom (UK)-based index scores range from -0.59 (worst health) to 1.0 (1.0=perfect health; Positive change from baseline=health improvement). Least Squares (LS) Mean value was adjusted for treatment group, cycle, treatment-by-cycle interaction, age, Eastern Cooperative Oncology Group (ECOG) performance status, stage of disease at study entry, and best response to previous chemotherapy.
Query!
Timepoint [10]
0
0
Baseline at Cycle 3, up to 30 days following treatment discontinuation
Query!
Secondary outcome [11]
0
0
Change From Baseline at Cycle 4 Baseline in EuroQol-5 Dimensions (EQ-5D) up to 30 Days Following Treatment Discontinuation
Query!
Assessment method [11]
0
0
EQ-5D consists of 5 items that assess participant's overall health. Participants choose 1 of 3 options that best describe status of each item. EQ-5D United Kingdom (UK)-based index scores range from -0.59 (worst health) to 1.0 (1.0=perfect health; Positive change from baseline=health improvement). Least Squares (LS) Mean value was adjusted for treatment group, cycle, treatment-by-cycle interaction, age, Eastern Cooperative Oncology Group (ECOG) performance status, stage of disease at study entry, and best response to previous chemotherapy.
Query!
Timepoint [11]
0
0
Baseline at Cycle 4, up to 30 days after treatment discontinuation
Query!
Secondary outcome [12]
0
0
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) During Cycle 1
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
After drug infusion in Cycle 1 (5 samples drawn over the 28-day cycle)
Query!
Secondary outcome [13]
0
0
Pharmacokinetics: Maximum Plasma Concentration (Cmax) During Cycle 2
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
After drug infusion in Cycle 2 (2 samples drawn over the 28-day cycle)
Query!
Eligibility
Key inclusion criteria
- Have a histologic and/or cytologic diagnosis of metastatic melanoma (Stage IV).
- Have the presence of evaluable disease as defined by the Response Evaluation Criteria
in Solid Tumors (RECIST 1.0).
- Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG)
Scale.
- Have progressed after 1 previous systemic treatment containing dacarbazine or
temozolomide for metastatic melanoma.
- Have discontinued all previous therapies for cancer, including chemotherapy,
radiotherapy, immunotherapy, or other investigational therapy for at least 30 days (6
weeks for mitomycin-C or nitrosoureas) before study enrollment and recovered from the
acute effects of therapy (except alopecia).
- Have a serum albumin level greater than or equal to 3.0 grams per deciliter (g/dL) or
greater than or equal to 30 grams per liter (g/L).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have received greater than or equal to 2 previous chemotherapy-containing systemic
treatment regimens for metastatic melanoma. An immunotherapy or antibody-based regimen
(including biologic agents and vaccination-based treatments), or treatment with a
targeted agent (for example, BRAF or c-Kit inhibitor is not counted as a prior
treatment regimen for determining study eligibility, unless either was combined with a
cytotoxic drug).
- Have active central nervous system (CNS) or leptomeningeal metastasis (brain
metastasis) at the time of study entry. Participants with signs or symptoms of
neurological compromise should have appropriate radiographic imaging performed before
study entry to rule out occult brain metastasis. Participants with a history of a
solitary CNS metastasis previously treated with curative intent (for example,
stereotactic radiation or surgery) and not requiring steroids are eligible.
- Are receiving warfarin.
- Have primary ocular or mucosal melanoma.
- Any previous treatment with paclitaxel or a paclitaxel-containing regimen for
metastatic melanoma.
- Have serious concomitant disorders, including active bacterial, fungal, or viral
infection, incompatible with the study (at the discretion of the investigator).
- Have previously completed or withdrawn from this study or any other study
investigating tasisulam-sodium.
- Have a known hypersensitivity to paclitaxel or Cremophor EL (polyoxyethylated castor
oil).
- Are pregnant or lactating.
- Have received a recent (within 30 days before enrollment) or are receiving concurrent
yellow fever vaccination.
- Have known positive test results in human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBSAg), or hepatitis C antibodies (HCAb).
- Are unable to withhold dosing of non-steroidal anti-inflammatory drugs (NSAIDs) or
proton-pump inhibitors (PPIs) for at least 72 hours before and after treatment with
tasisulam-sodium.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
336
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Coffs Harbour
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Wollongong
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Townsville
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Woolloongabba
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [2]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [3]
0
0
4810 - Townsville
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nevada
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Dakota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Dakota
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Wisconsin
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Graz
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Innsbruck
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Vienna
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Antwerp
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Brussels
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Leuven
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Alberta
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Ontario
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Quebec
Query!
Country [39]
0
0
Finland
Query!
State/province [39]
0
0
Tampere
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Turku
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Bordeaux
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Dijon
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Grenoble
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Marseille
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Nantes
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Paris
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Toulouse
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Villejuif
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Berlin
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Buxtehude
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Essen
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Hannover
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Heilbronn
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Kiel
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Koeln
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Mainz
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Muenchen
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Muenster
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Quedlinburg
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Tuebingen
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Jerusalem
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Tel Hashomer
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Tel-Aviv
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Genova
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Milano
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Napoli
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Padova
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Siena
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Goyang-Si
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Seoul
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Leiden
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Maastricht
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Rotterdam
Query!
Country [74]
0
0
Norway
Query!
State/province [74]
0
0
Oslo
Query!
Country [75]
0
0
Norway
Query!
State/province [75]
0
0
Trondheim
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Bialystok
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Gdansk
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Otwock
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Poznan
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Barcelona
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Madrid
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Pamplona
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Valencia
Query!
Country [84]
0
0
Sweden
Query!
State/province [84]
0
0
Malmo
Query!
Country [85]
0
0
Sweden
Query!
State/province [85]
0
0
Stockholm
Query!
Country [86]
0
0
Taiwan
Query!
State/province [86]
0
0
Changhua
Query!
Country [87]
0
0
Taiwan
Query!
State/province [87]
0
0
Niao Sung Hsiang
Query!
Country [88]
0
0
Taiwan
Query!
State/province [88]
0
0
Taipei
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Tao-Yuan
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Cambridgeshire
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Greater London
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Hants
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
London
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Middlesex
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary purpose of this study was to see how tasisulam-sodium affected metastatic
melanoma when compared against paclitaxel as measured by overall survival.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01006252
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01006252
Download to PDF